Medical AI startup OpenEvidence has successfully raised $250 million in its latest funding round, bringing its valuation to a staggering $12 billion. This marks a significant milestone for the company, which has seen its market value double in just three months, following a previous funding round in October that valued it at approximately $6 billion.
The Series D funding round, co-led by Thrive Capital and DST Global, reflects a growing investor interest in artificial intelligence tools tailored for healthcare and clinical decision-making. With this latest capital injection, OpenEvidence has now raised nearly $700 million in total, positioning itself as a key player in the healthcare AI market.
OpenEvidence’s innovative platform is designed to assist physicians by providing rapid access to medical knowledge, addressing a crucial need in clinical settings. The company’s technology facilitates the synthesis of information from peer-reviewed journals and established clinical guidelines, enhancing the decision-making capabilities of medical professionals. Currently, over 40% of physicians in the United States utilize OpenEvidence’s tools, which span more than 10,000 hospitals and medical centers.
Founded by Daniel Nadler, OpenEvidence has quickly established itself in the medical AI landscape. The recent influx of funding aligns with broader trends in the sector, as investment in generative AI increasingly shifts from consumer-focused applications to specialized industries like healthcare. Investors are recognizing the commercial viability and clinical relevance of AI applications that can support physicians in their daily tasks.
In an effort to tackle concerns regarding trust and reliability in AI systems—often cited as barriers to adoption in healthcare—OpenEvidence restricts its training data to verified medical sources. The company has also formed formal partnerships with respected organizations such as the New England Journal of Medicine and the American Medical Association, aimed at ensuring accuracy and transparency in the delivery of clinical information.
The growth of OpenEvidence’s platform over the past year has been remarkable. The company reported that it supported approximately 18 million clinical consultations from verified US physicians in December, a steep increase from around 3 million consultations per month a year earlier. This surge in usage underscores the demand for AI-driven tools in medical practice, as healthcare professionals seek efficient ways to enhance patient care.
OpenEvidence emphasizes that its technology serves as a clinical support tool rather than a replacement for physician judgment. Its AI models are designed to assist healthcare providers, acknowledging the importance of human expertise in medical decision-making. This distinction may help alleviate some concerns regarding the role of AI in clinical settings.
The company plans to utilize the newly acquired capital to bolster its research and development efforts and further scale its AI architecture. By routing physician queries to specialized medical AI models, OpenEvidence aims to improve both relevance and performance in various clinical contexts.
As the demand for AI solutions in healthcare continues to grow, OpenEvidence is well-positioned to capitalize on this trend. The significant funding and strategic partnerships could accelerate the adoption of its technology, potentially transforming the landscape of clinical decision-making in the years to come.
See also
Bank of America Warns of Wage Concerns Amid AI Spending Surge
OpenAI Restructures Amid Record Losses, Eyes 2030 Vision
Global Spending on AI Data Centers Surpasses Oil Investments in 2025
Rigetti CEO Signals Caution with $11 Million Stock Sale Amid Quantum Surge
Investors Must Adapt to New Multipolar World Dynamics
